Received Dec 22, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | UNK | — | — |
| PNC21 | PNEUMO (CAPVAXIVE) | MERCK & CO. INC. | UNK | Z005765 | — |
No side effects or symptoms reported. No additional AE; a patient received CAPVAXIVE on 11/04/2025 and then was administered a dose of PREVNAR 20 on 11/22/2025.; This spontaneous report was received from a Physician Assistant and refers to a male patient of unknown age. The patient's concurrent conditions, medical history, previous drug reactions, drug allergies and concomitant therapies were not reported. On 04-Nov-2025, the patient was vaccinated with Pneumococcal 21-valent Conjugate Vaccine (CAPVAXIVE INJ 168 mcg/ml) 0.5 mL (route of administration and site of administration were not provided), lot # Z005765 has been verified to be valid, expiration date not reported but upon internal validation established as 23-Nov-2026, given as prophylaxis. On 22-Nov-2025, the patient was administered a dose of PREVNAR 20 (dose, frequency, route of administration, lot #, expiration date, and indication were not provided) (Inappropriate schedule of product administration). No additional AE.